Evolent Health (EVH) grants 28,790 RSUs to Chief Accounting Officer

Rhea-AI Filing Summary

Shams Aammaad reported acquisition or exercise transactions in this Form 4 filing.

Evolent Health, Inc. reported that Chief Accounting Officer Shams Aammaad received a grant of 28,790 shares of Class A Common Stock in the form of restricted stock units under the Amended and Restated 2015 Omnibus Incentive Compensation Plan. These RSUs vest 34% on July 1, 2027 and 33% on July 1, 2028 and July 1, 2029. After this award, he holds 95,637 shares, including RSUs from prior grants.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shams Aammaad

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	28,790	$0.00	--

Holdings After Transaction: Class A Common Stock — 95,637 shares (Direct, null)

Footnotes (1)

1. Represents restricted stock units granted to Mr. Shams pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. Represents a portion of the award approved by the Compensation Committee of the Company's Board of Directors as part of the annual award cycle. The first portion of the award was granted on March 2, 2026, and this portion of the award was granted on July 1, 2026, following the issuance of additional shares under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. The Company's shareholders approved the issuance of additional shares under the Amended and Restated 2015 Omnibus Incentive Compensation Plan on June 4, 2026, at the Company's Annual Meeting. Securities vest at a rate of 34% on July 1, 2027, and 33% on July 1, 2028, and July 1, 2029. Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

Key Figures

RSU grant size: 28,790 shares Grant price: $0.00 per share Holdings after transaction: 95,637 shares +4 more

7 metrics

RSU grant size 28,790 shares Restricted stock units granted July 1, 2026

Grant price $0.00 per share Equity award, no cash purchase price

Holdings after transaction 95,637 shares Total Class A Common Stock reported following grant

First vesting tranche 34% Vests on July 1, 2027

Second vesting tranche 33% Vests on July 1, 2028

Third vesting tranche 33% Vests on July 1, 2029

Shareholder approval date June 4, 2026 Approval of additional shares under 2015 Omnibus Plan

Key Terms

restricted stock units, Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, Compensation Committee, annual award cycle, +1 more

5 terms

restricted stock units financial

"Represents restricted stock units granted to Mr. Shams pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan financial

"Represents restricted stock units granted to Mr. Shams pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan."

Compensation Committee financial

"Represents a portion of the award approved by the Compensation Committee of the Company's Board of Directors as part of the annual award cycle."

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

annual award cycle financial

"Represents a portion of the award approved by the Compensation Committee of the Company's Board of Directors as part of the annual award cycle."

vest financial

"Securities vest at a rate of 34% on July 1, 2027, and 33% on July 1, 2028, and July 1, 2029."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/06/2026 - 04:10 PM Accepted by SEC EDGAR 07/06/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shams Aammaad

(Last) (First) (Middle)

C/O EVOLENT HEALTH, INC.

1812 N. MOORE ST., STE. 1705

(Street)

ARLINGTON VIRGINIA 22209

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evolent Health, Inc. [ EVH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock(1)	07/01/2026		A		28,790(2)(3)	A	$0	95,637(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units granted to Mr. Shams pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

2. Represents a portion of the award approved by the Compensation Committee of the Company's Board of Directors as part of the annual award cycle. The first portion of the award was granted on March 2, 2026, and this portion of the award was granted on July 1, 2026, following the issuance of additional shares under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. The Company's shareholders approved the issuance of additional shares under the Amended and Restated 2015 Omnibus Incentive Compensation Plan on June 4, 2026, at the Company's Annual Meeting.

3. Securities vest at a rate of 34% on July 1, 2027, and 33% on July 1, 2028, and July 1, 2029.

4. Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

Remarks:

	/s/ Jonathan Weinberg, Attorney-in-fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Evolent Health (EVH) disclose in this Form 4 for Shams Aammaad?

Evolent Health disclosed that Chief Accounting Officer Shams Aammaad received 28,790 restricted stock units of Class A Common Stock as a compensation grant under the company’s 2015 Omnibus Incentive Compensation Plan, increasing his total reported holdings to 95,637 shares including prior RSU awards.

Is the Evolent Health (EVH) Form 4 transaction a stock purchase or sale?

The Form 4 shows a grant of restricted stock units, not a market purchase or sale. The transaction is coded as an acquisition (grant/award), with no cash price per share, reflecting equity-based compensation approved through the company’s normal annual award cycle.

How do the new Evolent Health (EVH) RSUs for Shams Aammaad vest over time?

The newly granted restricted stock units vest in stages over three years. According to the disclosure, 34% vest on July 1, 2027, and 33% vest on each of July 1, 2028 and July 1, 2029, subject to the usual award conditions.

What plan governs the Evolent Health (EVH) RSU grant to Shams Aammaad?

The RSU grant was made under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. Shareholders approved additional shares for issuance under this plan on June 4, 2026, enabling the company to complete this portion of the annual award.

How large is Shams Aammaad’s total reported Evolent Health (EVH) holding after this grant?

After the July 1, 2026 RSU grant, Shams Aammaad is reported to hold 95,637 shares of Class A Common Stock. This figure includes restricted stock units from this award and prior awards previously reported on Form 4 filings with the Securities and Exchange Commission.